Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in
drug-delivery platforms focused on its patented DehydraTECH-based,
drug-delivery technology and formulation development. A recent article
discussing the company reads, “Earlier this year, Lexaria moved into its new
head office that includes a Health Canada-licensed research and development
laboratory that is being used to conduct world-leading research into
drug-delivery methods and improvements. In addition to accelerating research in
the company’s DehydraTECH drug-delivery platform, Lexaria is also considering
issuing a limited commercial release of DehydraTECH version 2.0, which has been
shown to deliver 811% more CBD into animal blood than generic industry control
formulations, the company stated in an update to shareholders (http://ibn.fm/cWL3T). . . .
Lexaria’s focus on pioneering new technologies that can more efficiently
deliver APIs into the bloodstream, where they can have their desired effect,
includes developing an effective way to cross the blood-brain-barrier.
Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing
indicated 1,937% more CBD reached animal brain tissue compared to generic
industry control formulations.”
To view the full article, visit http://ibn.fm/fgTrB
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery platforms.
The company’s patented DehydraTECH drug-delivery technology changes the way
active pharmaceutical ingredients enter the bloodstream, promoting healthier
ingestion methods, lower overall dosing and higher effectiveness for lipophilic
active molecules. DehydraTECH increases bioabsorption, reduces time of onset
and masks unwanted tastes for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”),
nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple
companies in the cannabis industry for use in cannabinoid beverages, edibles
and oral products, as well as to a world-leading tobacco producer for the
development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment